Cargando…

Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy

BACKGROUND: Since the definition of different histologic subtypes of urothelial carcinomas by the World Health Organization (WHO) 2004 classification, description of molecular features and clinical behavior of these variants has gained more attention. METHODS: We reviewed 205 tumor samples of patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keck, Bastian, Wach, Sven, Stoehr, Robert, Kunath, Frank, Bertz, Simone, Lehmann, Jan, Stöckle, Michael, Taubert, Helge, Wullich, Bernd, Hartmann, Arndt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572418/ https://www.ncbi.nlm.nih.gov/pubmed/23394492 http://dx.doi.org/10.1186/1471-2407-13-71

Ejemplares similares

Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort
por: Weyerer, Veronika, et al.
Publicado: (2021)

Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy
por: Eckstein, Markus, et al.
Publicado: (2020)

Immune Cell-Associated Protein Expression Helps to Predict Survival in Muscle-Invasive Urothelial Bladder Cancer Patients after Radical Cystectomy and Optional Adjuvant Chemotherapy
por: Taubert, Helge, et al.
Publicado: (2021)

Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study
por: Rogler, Anja, et al.
Publicado: (2014)

Molecular Composition of Genomic TMPRSS2-ERG Rearrangements in Prostate Cancer
por: Krumbholz, Manuela, et al.
Publicado: (2019)

A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy
por: Eckstein, Markus, et al.
Publicado: (2018)

FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy
por: Sikic, Danijel, et al.
Publicado: (2020)

HLA-E expression and its clinical relevance in human renal cell carcinoma
por: Seliger, Barbara, et al.
Publicado: (2016)

Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis
por: Sikic, Danijel, et al.
Publicado: (2017)

Analysis of CXCL9, PD1 and PD-L1 mRNA in Stage T1 Non-Muscle Invasive Bladder Cancer and Their Association with Prognosis
por: Kubon, Jennifer, et al.
Publicado: (2020)

Differential prognostic value of MYC immunohistochemistry in subtypes of papillary renal cell carcinoma
por: Bellut, Julia, et al.
Publicado: (2017)

High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer
por: Sikic, Danijel, et al.
Publicado: (2021)

Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma
por: Kahlmeyer, Andreas, et al.
Publicado: (2019)

Reduced Recurrence Rates Are Associated with Photodynamic Diagnostics Compared to White Light after Extended Transurethral Resection of Bladder Tumors
por: Marquardt, Alexander, et al.
Publicado: (2022)

Serum miRNAs Support the Indication for MRI-Ultrasound Fusion-Guided Biopsy of the Prostate in Patients with Low-PI-RADS Lesions
por: Keck, Bastian, et al.
Publicado: (2021)

The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer
por: Sikic, Danijel, et al.
Publicado: (2021)

CREB1 is affected by the microRNAs miR-22-3p, miR-26a-5p, miR-27a-3p, and miR-221-3p and correlates with adverse clinicopathological features in renal cell carcinoma
por: Friedrich, Michael, et al.
Publicado: (2020)

CCL2 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Shows Divergent Prognostic Potential for Bladder Cancer Patients Depending on Lymph Node Stage
por: Eckstein, Markus, et al.
Publicado: (2020)

Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients
por: Eckstein, Markus, et al.
Publicado: (2021)

Characterization of the expression and immunological impact of the transcriptional activator CREB in renal cell carcinoma
por: Friedrich, Michael, et al.
Publicado: (2020)

TERT Promoter Mutation Analysis of Whole-Organ Mapping Bladder Cancers
por: Weyerer, Veronika, et al.
Publicado: (2021)

Piwi-like 1 protein expression is a prognostic factor for renal cell carcinoma patients
por: Stöhr, Christine G., et al.
Publicado: (2019)

Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review
por: Kunath, Frank, et al.
Publicado: (2012)

Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients
por: Weyerer, Veronika, et al.
Publicado: (2021)

Piwi-like 1 and -2 protein expression levels are prognostic factors for muscle invasive urothelial bladder cancer patients
por: Eckstein, Markus, et al.
Publicado: (2018)

Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients
por: Lieb, Verena, et al.
Publicado: (2021)

Cell-Free DNA Sequencing Reveals Gene Variants in DNA Damage Repair Genes Associated with Prognosis of Prostate Cancer Patients
por: Lieb, Verena, et al.
Publicado: (2022)

High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer
por: Sikic, Danijel, et al.
Publicado: (2017)

Expression of GP88 (Progranulin) Protein Is an Independent Prognostic Factor in Prostate Cancer Patients
por: Abdulrahman, Amer, et al.
Publicado: (2019)

Early versus deferred androgen suppression therapy for patients with lymph node-positive prostate cancer after local therapy with curative intent: a systematic review
por: Kunath, Frank, et al.
Publicado: (2013)

MicroRNA profiles classify papillary renal cell carcinoma subtypes
por: Wach, S, et al.
Publicado: (2013)

RNA Sequencing of Collecting Duct Renal Cell Carcinoma Suggests an Interaction between miRNA and Target Genes and a Predominance of Deregulated Solute Carrier Genes
por: Wach, Sven, et al.
Publicado: (2019)

Risk Factor Analysis for Long-Term Graft Survival Following Pediatric Kidney Transplantation: The Importance of Pretransplantation Time on Dialysis and Donor/Recipient Age Difference
por: Marcou, Marios, et al.
Publicado: (2023)

Do urology journals enforce trial registration? A cross-sectional study of published trials
por: Kunath, Frank, et al.
Publicado: (2011)

Expression of AR-V7 (Androgen Receptor Variant 7) Protein in Granular Cytoplasmic Structures Is an Independent Prognostic Factor in Prostate Cancer Patients
por: König, Paul, et al.
Publicado: (2020)

Combined miR-486 and GP88 (Progranulin) Serum Levels Are Suggested as Supportive Biomarkers for Therapy Decision in Elderly Prostate Cancer Patients
por: Fichte, Alexander, et al.
Publicado: (2022)

Long‐Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High‐Risk Bladder Cancer (Ta, Tis, T1, T2)
por: Merten, Ricarda, et al.
Publicado: (2019)

Endogenous Retroviral–K Envelope Is a Novel Tumor Antigen and Prognostic Indicator of Renal Cell Carcinoma
por: Weyerer, Veronika, et al.
Publicado: (2021)

Association of Tissue mRNA and Serum Antigen Levels of Members of the Urokinase-Type Plasminogen Activator System with Clinical and Prognostic Parameters in Prostate Cancer
por: Al-Janabi, Omar, et al.
Publicado: (2014)

NAD(P)H:Quinone Oxidoreductase 1 (NQO1) P187S Polymorphism and Prostate Cancer Risk in Caucasians
por: Stoehr, Christine G., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_0putpf58m6237mvmqg80h7fi16